Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages (Q38012791)

27 August 2017

Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages (English)

1 reference

27 August 2017

1 reference

Rodrigo Affonseca Bressan

5

0 references

Elisa Brietzke

6

object named as

Elisa Brietzke

1 reference

27 August 2017

Rodrigo Barbachan Mansur

1

1 reference

27 August 2017

André Zugman

2

1 reference

27 August 2017

Elson de Miranda Asevedo

3

1 reference

27 August 2017

Graccielle Rodrigues da Cunha

4

1 reference

27 August 2017

language of work or name

1 reference

1 June 2012

1 reference

Psychiatry and Clinical Neurosciences

27 August 2017

1 reference

27 August 2017

66

1 reference

27 August 2017

4

1 reference

27 August 2017

247-260

1 reference

A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology

27 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

A systematic review of the prevalence of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Monitoring and care of young people at incipient risk of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Early Intervention for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The role of neural stem cells for in vitro models of schizophrenia: neuroprotection via Akt/ERK signal regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Prenatal infection and schizophrenia: a review of epidemiologic and translational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokines and the nervous system. I: Expression and recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

TNF-alpha as a molecular target in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

"Inflammatory" cytokines: neuromodulators in normal brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Immune modulation of learning, memory, neural plasticity and neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

A dual role for interleukin-1 in hippocampal-dependent memory processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Increased mortality and spatial memory deficits in TNF-alpha-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Immune signalling in neural development, synaptic plasticity and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The neuropoietic cytokine family in development, plasticity, disease and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Neurodevelopmental effects of chronic exposure to elevated levels of pro-inflammatory cytokines in a developing visual system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Dysconnectivity in schizophrenia: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The development of the subplate and thalamocortical connections in the human foetal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Efficient derivation of functional floor plate tissue from human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Neuroglial activation and neuroinflammation in the brain of patients with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The role of cytokines in the pathophysiology of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The phenomenological critique and self-disturbance: implications for ultra-high risk ("prodrome") research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Prospective investigations of the prodromal state of schizophrenia: review of studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

What factors are related to delayed treatment in individuals at high risk for psychosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal VBM-fMRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Spatial working memory ability is a marker of risk-for-psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Neurocognitive indicators of clinical high-risk states for psychosis: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Early intervention in patients at ultra high risk of psychosis: benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Decreased interleukin-2 production in Korean schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Neonatal intrahippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Single-nucleotide polymorphisms in the interleukin-10 gene: differences in frequencies, linkage disequilibrium patterns, and haplotypes in three United States ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The value of interleukin-12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Association between −G308A tumor necrosis factor alpha gene polymorphism and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Tumor necrosis factor haplotype analysis amongst schizophrenia probands from four distinct populations in the Asia-Pacific region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Polymorphisms of interleukin‐4 promoter and receptor gene for schizophrenia in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia--a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

A Systematic Review and Meta-analysis of Northern Hemisphere Season of Birth Studies in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Effects of prenatal infection on brain development and behavior: a review of findings from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Late N-acetylcysteine treatment prevents the deficits induced in the offspring of dams exposed to an immune stress during gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Prenatal inflammation-induced hypoferremia alters dopamine function in the adult offspring in rat: relevance for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

White matter changes in schizophrenia: evidence for myelin-related dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Acute maternal stress in pregnancy and schizophrenia in offspring: a cohort prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Childhood abuse as a risk factor for psychotic experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Impact of child sexual abuse on mental health: prospective study in males and females

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Psychosis, victimisation and childhood disadvantage: evidence from the second British National Survey of Psychiatric Morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The neurobiological toll of child abuse and neglect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Rearing experiences and stress-induced plasma cortisol as early risk factors for excessive alcohol consumption in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The long-term psychobiological consequences of intermittent postnatal separation in the squirrel monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Childhood parental loss and adult hypothalamic-pituitary-adrenal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Low early-life social class leaves a biological residue manifested by decreased glucocorticoid and increased proinflammatory signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Neuroendocrine regulation of autoimmune/inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Slowing of wound healing by psychological stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Stressor-induced alteration of cytokine production in multiple sclerosis patients and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokine dysregulation associated with exam stress in healthy medical students.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokines and the brain: implications for clinical psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Adverse childhood experiences and self-reported liver disease: new insights into the causal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cumulative childhood stress and autoimmune diseases in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokines in schizophrenia and the effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Cytokines and schizophrenia: Microglia hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Celecoxib augmentation of continuously ill patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

The effects of celecoxib augmentation on cytokine levels in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Immune System and Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Psychotic symptoms in non-clinical populations and the continuum of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2012.02354.X

10.1111/J.1440-1819.2012.02354.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference